Multimodal Nanoparticles for Targeted Inflammation Resolution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nanocarriers for delivering therapeutics face challenges such as low encapsulation efficiency, poor sustained release, short blood circulation half-life, and lack of selectivity to target cells or tissues, which hinders their extensive application in treating inflammatory conditions like atherosclerosis and other diseases.
Innovation Solution
Development of sub-100 micron multimodal nanoparticles with a targeting element, a diagnostic or therapeutic agent, a stealth layer for immune evasion, and a biodegradable polymeric core for sustained release, specifically designed to bind to inflamed cells or tissues and enhance inflammation resolution.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current nanocarriers are used for delivering therapeutics, then delivery to target cells or tissues is achieved, but selectivity is poor and blood circulation half-life is short
Solution Approach 1:
The nanoparticle is designed with heterogeneous surface properties: a stealth coating (PEG) covering most of the surface for circulation stability, while localized regions expose targeting ligands (antibodies, peptides, or aptamers) that specifically bind to inflamed endothelium. This local quality differentiation resolves the contradiction between achieving selectivity and maintaining circulation half-life.
Solution Approach 2:
The nanoparticle comprises composite materials including a polymeric core, stealth coating (PEG), and biological targeting ligands. This composite structure integrates the circulation-stabilizing properties of PEG with the target-specific binding properties of antibodies or peptides, simultaneously achieving both long circulation half-life and high selectivity for inflamed tissues.
2Quantity of substance
If current nanocarriers are used for delivering therapeutics, then therapeutic delivery is achieved, but encapsulation efficiency is low and sustained release is poor
Solution Approach 1:
The patent optimizes parameters including nanoparticle size (50-200 nm), polymeric core composition, and drug-to-polymer ratio to maximize encapsulation efficiency. The controlled degradation rate of the polymeric core is tuned to achieve sustained release over 24-72 hours, resolving the contradiction between high encapsulation and prolonged release.
3Reliability
If nanoparticles are designed with multiple components for targeting and stealth properties, then selectivity and circulation half-life are improved, but device complexity increases
Solution Approach 1:
Multiple functional components (stealth PEG coating, targeting ligands, therapeutic payload, and imaging agents) are merged into a single integrated nanoparticle platform. This consolidation achieves high selectivity and circulation stability while simplifying the overall delivery system compared to using separate agents for each function.
Solution Approach 2:
The nanoparticle platform is designed with universal multi-functionality: the same core structure can accommodate different therapeutic agents (anti-inflammatory drugs, peptides), targeting ligands for different inflammatory conditions, and various imaging modalities. This universality reduces complexity by using a single platform design for multiple applications.
Data Source
AI summary
Sub-100 micron multimodal nanoparticles have four main components: 1) a target element (peptides, lipids, antibodies, small molecules, etc.) that can selectively bind to cells, tissues, or organs of the body; 2) a diagnostic agent such as a fluorophore or NMR contrast agent that allows visualization of nanoparticles at the site of delivery and/or a therapeutic or prophylactic agent; 3) an outside “stealth” layer that allows the particles to evade recognition by immune system components and increase particle circulation half-life; and 4) a biodegradable polymeric material, forming an inner core which can carry therapeutics and release the payloads at a sustained rate after systemic, intraperitoneal, or mucosal administration. These particles possess excellent stability, high loading efficiency, multiple agent encapsulation, targeting and imaging. They are targeted to sites of, or associated with, inflammation caused by a disease, disorder; trauma, chemotherapy or radiation.